KCA
Search
- Page Path
- HOME > Search
Original Articles
- Pediatric cancer
- Effectiveness and Safety of Clofarabine Monotherapy or Combination Treatment in Relapsed/Refractory Childhood Acute Lymphoblastic Leukemia: A Pragmatic, Non-interventional Study in Korea
- Jung Yoon Choi, Che Ry Hong, Kyung Taek Hong, Hyoung Jin Kang, Seongkoo Kim, Jae Wook Lee, Pil Sang Jang, Nack-Gyun Chung, Bin Cho, Hyery Kim, Kyung-Nam Koh, Ho Joon Im, Jong Jin Seo, Seung Min Hahn, Jung Woo Han, Chuhl Joo Lyu, Eu Jeen Yang, Young Tak Lim, Keon Hee Yoo, Hong Hoe Koo, Hoon Kook, In Sang Jeon, Hana Cho, Hee Young Shin
- Cancer Res Treat. 2021;53(4):1184-1194. Published online January 4, 2021
- DOI: https://doi.org/10.4143/crt.2020.289
-
Abstract
PDF
Supplementary Material
PubReader
ePub - Purpose
Effectiveness and safety of clofarabine (one of the treatment mainstays in pediatric patients with relapsed/refractory acute lymphoblastic leukemia [ALL]) was assessed in Korean pediatric patients with ALL to facilitate conditional coverage with evidence development.
Materials and Methods
In this multicenter, prospective, observational study, patients receiving clofarabine as mono/combination therapy were followed up every 4-6 weeks for 6 months or until hematopoietic stem cell transplantation (HSCT). Response rates, survival outcomes, and adverse events were assessed.
Results
Sixty patients (2-26 years old; 65% B-cell ALL, received prior ≥ 2 regimen, 68.3% refractory to previous regimen) were enrolled and treated with at least one dose of clofarabine; of whom 26 (43.3%) completed 6 months of follow-up after the last dose of clofarabine. Fifty-eight patients (96.7%) received clofarabine combination therapy. Overall remission rate (complete remission [CR] or CR without platelet recovery [CRp]) was 45.0% (27/60; 95% confidence interval [CI], 32.4 to 57.6) and the overall response rate (CR, CRp, or partial remission [PR]) was 46.7% (28/60; 95% CI, 34.0 to 59.3), with 11 (18.3%), 16 (26.7%), and one (1.7%) patients achieving CR, CRp, and PR, respectively. The median time to remission was 5.1 weeks (95% CI, 4.7 to 6.1). Median duration of remission was 16.6 weeks (range, 2.0 to 167.6 weeks). Sixteen patients (26.7%) proceeded to HSCT. There were 24 deaths; 14 due to treatment-emergent adverse events.
Conclusion
Remission with clofarabine was observed in approximately half of the study patients who had overall expected safety profile; however, there was no favorable long-term survival outcome in this study. -
Citations
Citations to this article as recorded by
- Revolutionizing cancer treatment: ROS-induced apoptosis via nanoformulated alkaloids
Swathi Putta, Santhosh Kumar Chinnaiyan, Ramadevi Korni, Venkata Radha Gadela
Journal of Drug Delivery Science and Technology.2025; 104: 106556. CrossRef - Proteomic analysis reveals chromatin remodeling as a potential therapeutical target in neuroblastoma
Zan Liu, Zitong Zhao, Longlong Xie, Zhenghui Xiao, Ming Li, Yong Li, Ting Luo
Journal of Translational Medicine.2025;[Epub] CrossRef - 3′-O-β-Glucosylation of nucleoside analogues using a promiscuous bacterial glycosyltransferase
Jonathan P. Dolan, Tessa Keenan, Aisling Ní Cheallaigh, Martin A. Fascione, Gavin J. Miller
RSC Chemical Biology.2025;[Epub] CrossRef - Opciones para el tratamiento de la recaída en leucemia linfoblástica aguda. Revisión de tema
Christian Omar Ramos-Peñafiel, Carlos Martínez-Murillo, Daniela Pérez-Sámano, Camila Terreros-Palacios, Adán Germán Gallardo-Rodríguez, Irma Olarte-Carrillo, Adolfo Martínez-Tovar
Revista Médicas UIS.2024;[Epub] CrossRef - Clofarabine
Reactions Weekly.2023; 1958(1): 155. CrossRef - Patient-Level Meta-analysis of Clofarabine in Acute Lymphoblastic Leukemia
Sima Jeha, Hiroaki Goto, André Baruchel, Emmanuelle Boëlle-Le Corfec, Christine Geffriaud-Ricouard, Rob Pieters, Hee Young Shin
Advances in Therapy.2023; 40(12): 5447. CrossRef - Novel Treatments for Pediatric Relapsed or Refractory Acute B-Cell Lineage Lymphoblastic Leukemia: Precision Medicine Era
Shang Mengxuan, Zhou Fen, Jin Runming
Frontiers in Pediatrics.2022;[Epub] CrossRef
- Revolutionizing cancer treatment: ROS-induced apoptosis via nanoformulated alkaloids
- 8,317 View
- 200 Download
- 4 Web of Science
- 7 Crossref
- Clinical Characteristics and Treatment Outcomes of Pediatric Patients with Non-Hodgkin Lymphoma in East Asia
- Jin Kyung Suh, Yi-Jin Gao, Jing-Yan Tang, Shiann-Tarng Jou, Dong-Tsamn Lin, Yoshiyuki Takahashi, Seiji Kojima, Ling Jin, Yonghong Zhang, Jong Jin Seo
- Cancer Res Treat. 2020;52(2):359-368. Published online July 29, 2019
- DOI: https://doi.org/10.4143/crt.2019.219
-
Abstract
PDFPubReaderePub
- Purpose
The presentations and geographic incidence of pediatric non-Hodgkin lymphoma (NHL) differ from those of adults. This study delineated the characteristics and outcomes of pediatric NHL in East Asia.
Materials and Methods
Medical records of 749 pediatric patients with NHL treated at participating institutions in mainland China, Japan, Korea, and Taiwan from January 2008 to December 2013 were reviewed. Demographic and clinical features, survival outcomes, and putative prognostic factors were analyzed.
Results
Five hundred thirty patients (71%) were male. The most common pathologic subtypes were Burkitt lymphoma (BL) (36%). Six hundred seven patients (81%) had advanced diseases at diagnosis. The 5-year overall survival and event-free survival (EFS) rates were 89% and 84%. The 5-year EFS rates of BL, lymphoblastic lymphoma, and diffuse large B-cell lymphoma were 88%, 88%, and 89%, and those of anaplastic large cell lymphoma (ALCL) and peripheral T-cell lymphoma (PTCL) were 71% and 56% (p < 0.001). Central nervous system involvement, high lactate dehydrogenase level (> 250 IU/mL), and advanced disease at diagnosis (≥ stage III) were associated with poor outcomes (p < 0.05). ALCL and PTCL relapsed more frequently than other pathologic subtypes (p < 0.001).
Conclusion
In East Asia, PTCL was more frequent than in Western countries, and bone marrow involvement did not affect treatment outcome. This international study should motivate future collaborative study on NHL in East Asia. -
Citations
Citations to this article as recorded by- Evaluation of NHL subtypes, staging, and prognostic factors: A single-centric retrospective cohort study
Ulfat A. Wani, Umeek Jeelani, Sheikh A. Aziz, Bashrat Ara Wani, Gul M. Bhat, Kaneez Fatima, Shaheen N. Lone, Asifa Andleeb
Journal of Cancer Research and Therapeutics.2025; 21(1): 34. CrossRef - Hemoglobinopathies, merozoite surface protein-2 gene polymorphisms, and acquisition of Epstein Barr virus among infants in Western Kenya
Perez K. Olewe, Shehu Shagari Awandu, Elly O. Munde, Samuel B. Anyona, Evans Raballah, Asito S. Amolo, Sidney Ogola, Erick Ndenga, Clinton O. Onyango, Rosemary Rochford, Douglas J. Perkins, Collins Ouma
BMC Cancer.2023;[Epub] CrossRef - iTRAQ-Based Proteomic Analysis Reveals Potential Serum Biomarkers for Pediatric Non-Hodgkin’s Lymphoma
Runhong Yu, Linna Cheng, Shiwei Yang, Yufeng Liu, Zunmin Zhu
Frontiers in Oncology.2022;[Epub] CrossRef
- Evaluation of NHL subtypes, staging, and prognostic factors: A single-centric retrospective cohort study
- 9,264 View
- 397 Download
- 4 Web of Science
- 3 Crossref
- Risk Factor Analysis for Secondary Malignancy in Dexrazoxane-Treated Pediatric Cancer Patients
- Hyery Kim, Hyoung Jin Kang, Kyung Duk Park, Kyung-Nam Koh, Ho Joon Im, Jong Jin Seo, Jae Wook Lee, Nack-Gyun Chung, Bin Cho, Hack Ki Kim, Jae Min Lee, Jeong Ok Hah, Jun Ah Lee, Young Ho Lee, Sang Kyu Park, Hee Jo Baek, Hoon Kook, Ji Yoon Kim, Heung Sik Kim, Hwang Min Kim, Hee Won Chueh, Meerim Park, Hoi Soo Yoon, Mee Jeong Lee, Hyoung Soo Choi, Hyo Seop Ahn, Yoshifumi Kawano, Ji Won Park, Seokyung Hahn, Hee Young Shin
- Cancer Res Treat. 2019;51(1):357-367. Published online May 14, 2018
- DOI: https://doi.org/10.4143/crt.2017.457
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Purpose
Dexrazoxane has been used as an effective cardioprotector against anthracycline cardiotoxicity. This study intended to analyze cardioprotective efficacy and secondary malignancy development, and elucidate risk factors for secondary malignancies in dexrazoxane-treated pediatric patients.
Materials and Methods
Data was collected from 15 hospitals in Korea. Patients who received any anthracyclines, and completed treatment without stem cell transplantation were included. For efficacy evaluation, the incidence of cardiac events and cardiac event-free survival rates were compared. Data about risk factors of secondary malignancies were collected.
Results
Data of total 1,453 cases were analyzed; dexrazoxane with every anthracyclines group (D group, 1,035 patients) and no dexrazoxane group (non-D group, 418 patients). Incidence of the reported cardiac events was not statistically different between two groups; however, the cardiac event-free survival rate of patients with more than 400 mg/m2 of anthracyclines was significantly higher in D group (91.2% vs. 80.1%, p=0.04). The 6-year cumulative incidence of secondary malignancy was not different between both groups after considering follow-up duration difference (non-D, 0.52%±0.37%; D, 0.60%±0.28%; p=0.55). The most influential risk factor for secondary malignancy was the duration of anthracycline administration according to multivariate analysis.
Conclusion
Dexrazoxane had an efficacy in lowering cardiac event-free survival rates in patients with higher cumulative anthracyclines. As a result of multivariate analysis for assessing risk factors of secondary malignancy, the occurrence of secondary malignancy was not related to dexrazoxane administration. -
Citations
Citations to this article as recorded by- Exploring the effects of topoisomerase II inhibitor XK469 on anthracycline cardiotoxicity and DNA damage
Veronika Keresteš, Jan Kubeš, Lenka Applová, Petra Kollárová, Olga Lenčová-Popelová, Iuliia Melnikova, Galina Karabanovich, Mushtaq M Khazeem, Hana Bavlovič-Piskáčková, Petra Štěrbová-Kovaříková, Caroline A Austin, Jaroslav Roh, Martin Štěrba, Tomáš Šimůn
Toxicological Sciences.2024; 198(2): 288. CrossRef - Circ-0006332 stimulates cardiomyocyte pyroptosis via the miR-143/TLR2 axis to promote doxorubicin-induced cardiac damage
Ping Zhang, Yuanyuan Liu, Yuliang Zhan, Pengtao Zou, Xinyong Cai, Yanmei Chen, Liang Shao
Epigenetics.2024;[Epub] CrossRef - Pediatric Cardio-Oncology: Screening, Risk Stratification, and Prevention of Cardiotoxicity Associated with Anthracyclines
Xiaomeng Liu, Shuping Ge, Aijun Zhang
Children.2024; 11(7): 884. CrossRef - Efficacy of Dexrazoxane in Cardiac Protection in Pediatric Patients Treated With Anthracyclines
Parya Rahimi, Behsheed Barootkoob, Ahmed ElHashash, Arun Nair
Cureus.2023;[Epub] CrossRef - Inducing a Proinflammatory Response with Bioengineered Yeast Vacuoles with TLR2-Binding Peptides (VacT2BP) as a Drug Carrier for Daunorubicin Delivery
Wooil Choi, Woo-Ri Shin, Yang-Hoon Kim, Jiho Min
ACS Applied Materials & Interfaces.2023; 15(35): 41258. CrossRef - Circulating Biomarkers for Monitoring Chemotherapy-Induced Cardiotoxicity in Children
Luigia Meo, Maria Savarese, Carmen Munno, Peppino Mirabelli, Pia Ragno, Ornella Leone, Mariaevelina Alfieri
Pharmaceutics.2023; 15(12): 2712. CrossRef - Hyperhomocysteinemia as a Link of Chemotherapy-Related Endothelium Impairment
Ashot Avagimyan
Current Problems in Cardiology.2022; 47(10): 100932. CrossRef - Late health outcomes after dexrazoxane treatment: A report from the Children's Oncology Group
Eric J. Chow, Richard Aplenc, Lynda M. Vrooman, David R. Doody, Yuan‐Shung V. Huang, Sanjeev Aggarwal, Saro H. Armenian, K. Scott Baker, Smita Bhatia, Louis S. Constine, David R. Freyer, Lisa M. Kopp, Wendy M. Leisenring, Barbara L. Asselin, Cindy L. Schw
Cancer.2022; 128(4): 788. CrossRef - Primary cardioprotection with dexrazoxane in patients with childhood cancer who are expected to receive anthracyclines: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group
Esmée C de Baat, Elvira C van Dalen, Renée L Mulder, Melissa M Hudson, Matthew J Ehrhardt, Frederike K Engels, Elizabeth A M Feijen, Heynric B Grotenhuis, Jan M Leerink, Livia Kapusta, Gertjan J L Kaspers, Remy Merkx, Luc Mertens, Roderick Skinner, Wim J
The Lancet Child & Adolescent Health.2022; 6(12): 885. CrossRef - Cardiotoxicity After Anthracycline Chemotherapy for Childhood Cancer in a Multiethnic Asian Population
Varen Zhi Zheng Tan, Nicole Min Chan, Wai Lin Ang, Soe Nwe Mya, Mei Yoke Chan, Ching Kit Chen
Frontiers in Pediatrics.2021;[Epub] CrossRef - Early-onset Cardiotoxicity assessment related to anthracycline in children with leukemia. A Prospective Study
Adriana Linares Ballesteros, Roy Sanguino Lobo, Juan Camilo Villada Valencia, Oscar Arévalo Leal, Diana Constanza Plazas Hernández, Nelson Aponte Barrios, Iván Perdomo Ramírez
Colombia Medica.2021; 52(1): e2034542. CrossRef - Mechanisms and Insights for the Development of Heart Failure Associated with Cancer Therapy
Claire Fraley, Sarah A. Milgrom, Lavanya Kondapalli, Matthew R. G. Taylor, Luisa Mestroni, Shelley D. Miyamoto
Children.2021; 8(9): 829. CrossRef - Dantrolene Attenuates Cardiotoxicity of Doxorubicin Without Reducing its Antitumor Efficacy in a Breast Cancer Model
Valentina K. Todorova, Eric R. Siegel, Yihong Kaufmann, Asangi Kumarapeli, Aaron Owen, Jeanne Y. Wei, Issam Makhoul, V. Suzanne Klimberg
Translational Oncology.2020; 13(2): 471. CrossRef - Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase IIβ Interaction as a Prerequisite for Effective Protection against Anthracycline Cardiotoxicity
Petra Kollárová-Brázdová, Anna Jirkovská, Galina Karabanovich, Zuzana Pokorná, Hana Bavlovič Piskáčková, Eduard Jirkovský, Jan Kubeš, Olga Lenčová-Popelová, Yvona Mazurová, Michaela Adamcová, Veronika Skalická, Petra Štěrbová-Kovaříková, Jaroslav Roh, Tom
The Journal of Pharmacology and Experimental Therapeutics.2020; 373(3): 402. CrossRef - Anthracyclines/cyclophosphamide/etoposide
Reactions Weekly.2019; 1741(1): 28. CrossRef - Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series
Sarju Ganatra, Anju Nohria, Sachin Shah, John D. Groarke, Ajay Sharma, David Venesy, Richard Patten, Krishna Gunturu, Corrine Zarwan, Tomas G. Neilan, Ana Barac, Salim S. Hayek, Sourbha Dani, Shantanu Solanki, Syed Saad Mahmood, Steven E. Lipshultz
Cardio-Oncology.2019;[Epub] CrossRef - Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors
Neha Bansal, M. Jacob Adams, Sarju Ganatra, Steven D. Colan, Sanjeev Aggarwal, Rudolf Steiner, Shahnawaz Amdani, Emma R. Lipshultz, Steven E. Lipshultz
Cardio-Oncology.2019;[Epub] CrossRef - Cardiovascular safety of oncologic agents: a double-edged sword even in the era of targeted therapies – Part 2
Antonis A. Manolis, Theodora A. Manolis, Dimitri P. Mikhailidis, Antonis S. Manolis
Expert Opinion on Drug Safety.2018; 17(9): 893. CrossRef
- Exploring the effects of topoisomerase II inhibitor XK469 on anthracycline cardiotoxicity and DNA damage
- 10,426 View
- 334 Download
- 19 Web of Science
- 18 Crossref
- A Study on the Significance of Peripheral T-lymphocyte Subsets and Mitogen-induced Lymphocyte Prolicaraction in Acute Lymphoblastic Leukemia in Childhood
- Sang Hyun Byun, Jong Jin Seo, Young Hun Chung
- J Korean Cancer Assoc. 1990;22(2):257-267.
-
Abstract
PDF
- To evaluate the relationship between peripheral blood T-lymphocyte subsets, mitogen-induced lymphocyte proliferation and the outcome of acute lymphoblastic leukemia in childhood, the authors studied 15 cases of acute Iymphoblastic leukemia in childhood. The results were as follows: 1 I Percent peripheral lymphocyte and percent CDS+ cells showed no significant difference between total patient group and control group, while percent CD4+ cells was significantly decreased in total patient group compared to control group. But no significant difference was found between patient subgroups 2) Total counts of CD4+ cells and CD8+cells showed no significant difference between patient subgroups. 3) The ratio of CD4+cells and CDB+ cells showed no significant difference between patient subgroups, but more cases with the ratio less than 1.0 were found among total patient group compared to control group. 4) The stimulation indices of PHA and Con-A were significantly decreased in total patient group (p<0.05, p<0.005) compared to control group, but no significant difference was observed between patient subgroups. 5) The unstimulated 3[H]-thymidine uptake showed no significant relationship between patient subgroups. 6) The distribution of T-lymphocyte subsets showed no significant relationship with the stimula- tion index of PHA and Con-A. These results showed that the children with acute lymphoblastic leukemia have depressed cellular immune functions tested with T-lymphocvte subsets and mitagen-induced lymphocyte proliferation assay. But these results can not be regarded as one of prognostic factors of acute lymphoblastic leukemia in childhood unless there are additional longterm data indicating the T-cell mediated immune functions are related to the outcome of acute lymphoblastic leukemia in childhood.
- 2,395 View
- 13 Download
- Effect of rhGM-CSF on the Chemotherapy - induced Neutropenia of Children with Solid Tumors
- Jong Jin Seo, Sang Won Cha, Sang Mee Lee, Kyu Don Kim
- J Korean Cancer Assoc. 1995;27(2):322-331.
-
Abstract
PDF
- To investigate the clinical effectiveness of recombinant human GM-CSF(rhGM-CSF; Leucogen) on the chemotherapy-induced neutropenia, twelve children with malignant solid tumor who had neutropenia after chemotherapy received 250 pg/M(2)/day of rhGM-CSF subcutaneouly for 10 consecutive days from the fifth day of next chemotherapy were schedule using the same rekimen. rhGM-CSF significantly increased leukocyte, neutrophil and eosinophil counts on the tenth day of GM-CSF course compared to the control course(P<0.05), but there was no significant difference in the counts of monocyte, lymphocyte, platelet or hemoglobin(p>0.1). The nadir of leukocyte and neutrophil were significantly higher in GM-CSF course than those of control course (P<0.05), but there was no significant difference in that of monocyte, lymphocyte, eo- sinophil, platelet or hemoglobin(P: 0.1). The duration of chemotherapy-induced leukopenia and neutropenia were decreased significantly in GM-CSF course than those of control course(P< 0.05). The duration of antibiotics administration and febrile period during chemotherapy were shorter in GM-CSF course without statistical significance. No significant side effect was observed during rhGM-CSF course. These results indicate that rhGM-CSF(Leucogen') is effective in alleviating the chemotherapy-induced neutropenia of children with malignant solid tumors.
- 2,740 View
- 21 Download
First
Prev
